Protocols

The McGuire 2025 narrative review in Current Reviews in Musculoskeletal Medicine (18:611–619) concludes that BPC-157 demonstrates robust preclinical regenerative activity across muscle, tendon, ligament, bone, and cartilage — but that the absence of human clinical approval, an active FDA compounding ban, and unresolved oncological safety signals mean the compound sits in a genuine risk-benefit grey zone for practitioners in 2026.

The clearest human signal comes from Prasse et al. (2010), an open Phase 2 study in 20 histologically confirmed sarcoidosis patients: nebulized synthetic VIP (aviptadil) at 50 µg four times daily via ultrasonic nebulizer for 28 days significantly reduced TNF-α production by bronchoalveolar lavage (BAL) cells and expanded CD4+CD25+FoxP3+ regulatory T cells. No serious adverse events were recorded.

TRIUMPH-1 Phase 3 data show retatrutide dosed at 4 mg, 9 mg, or 12 mg once weekly via subcutaneous injection, escalated from a 2 mg starting dose over 20 weeks. The 12 mg arm produced 28.3% mean body-weight reduction at 80 weeks, exceeding tirzepatide's 22.5% ceiling at 15 mg in SURMOUNT-1, though no direct head-to-head trial has yet reported results.

A 2026 systems medicine review in Expert Review of Clinical Pharmacology synthesises major clinical trial data alongside proteomic and metabolomic evidence to map how semaglutide remodels inflammatory, lipid, and extracellular matrix (ECM) pathways across multiple organs. The picture that emerges is of a drug whose benefits extend well beyond glucose lowering and weight reduction into coordinated multi-system biology.

BRP (BRINP2-related peptide) is a naturally occurring 12-amino-acid peptide identified by Stanford researchers in 2025 using an AI-driven prohormone-cleavage prediction tool. It suppresses appetite via the hypothalamic cAMP–PKA–CREB–FOS cascade — a pathway entirely distinct from the GLP-1 receptor. Because BRP does not engage the area postrema, it produces equivalent food-intake reduction without triggering nausea or conditioned taste aversion.

Škrlec et al. (Applied Microbiology and Biotechnology, 2018) engineered Lactococcus lactis — a GRAS-status lactic acid bacterium — to produce and deliver BPC-157 via two strategies: cell-surface display with trypsin-mediated shedding, and direct secretion into the growth medium. The secretion strategy yielded superior antioxidant activity in cell-free supernatants, establishing L. lactis as a viable microbial chassis for oral BPC-157 delivery.

As of 2026, no completed randomised controlled trial has evaluated BPC-157 in human orthopaedic surgical populations. Preclinical models consistently show accelerated tendon and ligament repair through fibroblast activation, collagen remodelling, and angiogenesis. A July 2026 narrative review concludes that biological plausibility is established, but the human evidence gap remains the central unresolved barrier to clinical adoption.

The SELECT trial demonstrated that semaglutide 2.4 mg weekly reduced the three-point MACE composite by 20% versus placebo in adults with overweight or obesity and established CVD but without diabetes. The hazard ratio was statistically significant at HR 0·80 and the absolute risk reduction was approximately one and a half percentage points over a mean follow-up of approximately 40 months.

A 2026 review published in Expert Opinion on Drug Delivery (Nayak et al.) synthesises current semaglutide therapy trends and the principal strategies under investigation to overcome its sub-1% oral bioavailability. Subcutaneous formulations remain the clinical gold standard, while SNAC-enabled oral tablets, lipid nanoparticle carriers, and microneedle patch systems represent the leading next-generation delivery approaches.

The FDA's June 2026 wave of 25 warning letters to telehealth companies — combined with its standing position that retatrutide cannot be legally compounded — materially narrows the landscape for practitioners using GLP-1 peptide protocols. Compounded semaglutide and tirzepatide now face tighter sourcing requirements, while retatrutide products outside clinical trials carry no regulatory pathway whatsoever.

Compounded semaglutide occupies an increasingly narrow legal corridor in mid-2026. Bulk shortage-based compounding ended in April–May 2025, the FDA logged more than 1,700 adverse events by May 21, 2026, and on April 30, 2026 proposed excluding semaglutide from the 503B bulks list entirely. A limited patient-specific 503A pathway survives under strict documented-need conditions.

A 2026 review published in International Journal of Molecular Sciences (MDPI) synthesises preclinical evidence showing that BPC-157 — a 15-amino-acid pentadecapeptide derived from human gastric juice — accelerates tissue repair through angiogenesis, collagen synthesis, and FAK-paxillin signalling, while also attenuating pain via nitric oxide pathway modulation and central nociceptive mechanisms.